Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), or Direct Renin Inhibitors (DRI) for Adults With Hypertension

Slide: 1 of 16

Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), or Direct Renin Inhibitors (DRI) for Adults with Hypertension

This slide set is based on a comparative effectiveness review (CER) titled Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), and a Direct Renin Inhibitor (DRI) for Treating Essential Hypertension: An Update, which was developed by the Duke Evidence-based Practice Center for the Agency for Healthcare Research and Quality (AHRQ Contract No. 290-02-0025) and is available online. CERs are comprehensive systematic reviews of the literature and usually compare two or more types of treatments, such as different drugs, for the same condition. This CER on ACEIs, ARBs, and DRI for adults with hypertension is an update to the 2007 CER on ACEIs versus ARBs and expands to include comparisons with the DRI aliskiren. Data sources were taken from searches of MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, a list of systematic reviews underway in the Cochrane Hypertension Review Group, and selected gray literature sources. The review this slide set is based on included 97 studies (36 new since 2007) directly comparing ACEIs versus ARBs and three studies directly comparing aliskiren to ACEIs or ARBs.